- Home
- GNLX vs EDAP Comparison
GNLX vs EDAP Comparison
Compare GNLX & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- EDAP
- Stock Information
- Founded
- GNLX 2001
- EDAP 1979
- Country
- GNLX United States
- EDAP France
- Employees
- GNLX N/A
- EDAP N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- GNLX Health Care
- EDAP Health Care
- Exchange
- GNLX Nasdaq
- EDAP Nasdaq
- Market Cap
- GNLX 112.8M
- EDAP 53.8M
- IPO Year
- GNLX 2023
- EDAP 1997
- Fundamental
- Price
- GNLX $3.09
- EDAP N/A
- Analyst Decision
- GNLX Strong Buy
- EDAP Buy
- Analyst Count
- GNLX 4
- EDAP 3
- Target Price
- GNLX $17.75
- EDAP $8.50
- AVG Volume (30 Days)
- GNLX 137.5K
- EDAP 37.5K
- Earning Date
- GNLX 08-13-2025
- EDAP 08-27-2025
- Dividend Yield
- GNLX N/A
- EDAP N/A
- EPS Growth
- GNLX N/A
- EDAP N/A
- EPS
- GNLX N/A
- EDAP N/A
- Revenue
- GNLX N/A
- EDAP $67,840,467.00
- Revenue This Year
- GNLX N/A
- EDAP N/A
- Revenue Next Year
- GNLX N/A
- EDAP N/A
- P/E Ratio
- GNLX N/A
- EDAP N/A
- Revenue Growth
- GNLX N/A
- EDAP 3.69
- 52 Week Low
- GNLX $1.60
- EDAP $1.26
- 52 Week High
- GNLX $5.89
- EDAP $5.28
- Technical
- Relative Strength Index (RSI)
- GNLX 56.10
- EDAP 36.07
- Support Level
- GNLX $2.75
- EDAP $1.60
- Resistance Level
- GNLX $3.17
- EDAP $1.74
- Average True Range (ATR)
- GNLX 0.24
- EDAP 0.10
- MACD
- GNLX -0.00
- EDAP -0.01
- Stochastic Oscillator
- GNLX 56.94
- EDAP 27.59
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.